Raia Drogasil SA
BOVESPA:RADL3
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.98
30.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Raia Drogasil SA
Raia Drogasil SA
Accounts Receivables
Raia Drogasil SA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Raia Drogasil SA
BOVESPA:RADL3
|
Accounts Receivables
R$3.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
|
Empreendimentos Pague Menos SA
BOVESPA:PGMN3
|
Accounts Receivables
R$512.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Dimed SA Distribuidora de Medicamentos
BOVESPA:PNVL3
|
Accounts Receivables
R$385.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
d
|
d1000 Varejo Farma Participacoes SA
BOVESPA:DMVF3
|
Accounts Receivables
R$160.4m
|
CAGR 3-Years
31%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
Raia Drogasil SA
Glance View
Raia Drogasil SA is a leading retail pharmacy chain in Brazil, established through the merger of two prominent companies, Raia and Drogasil, creating a powerhouse in the pharmaceutical and personal care sectors. With a mission to cater to the healthcare and wellness needs of Brazilians, the company operates over 2,300 stores across key urban regions, boasting a comprehensive product range that includes prescription medications, over-the-counter drugs, beauty products, and health-related services. Investors are drawn to Raia Drogasil for its strong market position, supported by a consistent strategy of expansion, innovation, and a commitment to customer service, making it a trusted name in the fast-growing Brazilian pharmaceutical market. In recent years, Raia Drogasil has implemented advanced sales and inventory management systems to enhance operational efficiency and customer satisfaction. The company's focus on growth is further reinforced by a robust online presence, enabling it to capture emerging e-commerce trends among Brazilian consumers. With a resilient business model, anchored by a broad geographic footprint and an increasingly diverse product offering, Raia Drogasil stands poised for long-term success. As Brazil's middle class continues to expand and healthcare spending rises, the company presents a compelling opportunity for investors looking to tap into a thriving market with promising growth potential.
See Also
What is Raia Drogasil SA's Accounts Receivables?
Accounts Receivables
3.2B
BRL
Based on the financial report for Sep 30, 2024, Raia Drogasil SA's Accounts Receivables amounts to 3.2B BRL.
What is Raia Drogasil SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
24%
Over the last year, the Accounts Receivables growth was 15%. The average annual Accounts Receivables growth rates for Raia Drogasil SA have been 22% over the past three years , 22% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
